Literature DB >> 22409598

Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.

Suvi T M Orr1, Sharon L Ripp, T Eric Ballard, Jaclyn L Henderson, Dennis O Scott, R Scott Obach, Hao Sun, Amit S Kalgutkar.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22409598     DOI： 10.1021/jm300065h

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  28 in total

1.  Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment.

Authors:  Mark Ammirati; Scott W Bagley; Samit K Bhattacharya; Leonard Buckbinder; Anthony A Carlo; Rebecca Conrad; Christian Cortes; Robert L Dow; Matthew S Dowling; Ayman El-Kattan; Kristen Ford; Cristiano R W Guimarães; David Hepworth; Wenhua Jiao; Jennifer LaPerle; Shenping Liu; Allyn Londregan; Paula M Loria; Alan M Mathiowetz; Michael Munchhof; Suvi T M Orr; Donna N Petersen; David A Price; Athanasia Skoura; Aaron C Smith; Jian Wang
Journal:  ACS Med Chem Lett       Date:  2015-10-06       Impact factor: 4.345

2.  Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product-Drug Interactions: A NaPDI Center Recommended Approach.

Authors:  Emily J Johnson; Vanessa González-Peréz; Dan-Dan Tian; Yvonne S Lin; Jashvant D Unadkat; Allan E Rettie; Danny D Shen; Jeannine S McCune; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2018-05-07       Impact factor: 3.922

3.  The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes.

Authors:  Momir Mikov; Maja Đanić; Nebojša Pavlović; Bojan Stanimirov; Svetlana Goločorbin-Kon; Karmen Stankov; Hani Al-Salami
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-12       Impact factor: 2.441

4.  Numerical Analysis of Time-Dependent Inhibition by MDMA.

Authors:  John T Rodgers; Jeffrey P Jones
Journal:  Drug Metab Dispos       Date:  2019-10-22       Impact factor: 3.922

5.  Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349.

Authors:  Zhonghua Pei; Elizabeth Blackwood; Lichuan Liu; Shiva Malek; Marcia Belvin; Michael F T Koehler; Daniel F Ortwine; Huifen Chen; Frederick Cohen; Jane R Kenny; Philippe Bergeron; Kevin Lau; Cuong Ly; Xianrui Zhao; Anthony A Estrada; Tom Truong; Jennifer A Epler; Jim Nonomiya; Lan Trinh; Steve Sideris; John Lesnick; Linda Bao; Ulka Vijapurkar; Sophie Mukadam; Suzanne Tay; Gauri Deshmukh; Yung-Hsiang Chen; Xiao Ding; Lori S Friedman; Joseph P Lyssikatos
Journal:  ACS Med Chem Lett       Date:  2012-11-29       Impact factor: 4.345

6.  A Cascade Reaction of Cinnamyl Azides with Acrylates Directly Generates Tetrahydro-Pyrrolo-Pyrazole Heterocycles.

Authors:  Angela S Carlson; En-Chih Liu; Joseph J Topczewski
Journal:  J Org Chem       Date:  2020-04-20       Impact factor: 4.354

7.  Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy.

Authors:  Nan Zhang; Ryan P Seguin; Kent L Kunze; Yan-Yan Zhang; Hyunyoung Jeong
Journal:  Drug Metab Dispos       Date:  2013-09-17       Impact factor: 3.922

8.  Endocannabinoid Virodhamine Is an Endogenous Inhibitor of Human Cardiovascular CYP2J2 Epoxygenase.

Authors:  Lauren N Carnevale; Andres S Arango; William R Arnold; Emad Tajkhorshid; Aditi Das
Journal:  Biochemistry       Date:  2018-11-06       Impact factor: 3.162

9.  Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System.

Authors:  Xiaojing Wang; Minghua Sun; Connie New; Spencer Nam; Wesley P Blackaby; Alastair J Hodges; David Nash; Mizio Matteucci; Joseph P Lyssikatos; Peter W Fan; Suzanne Tay; Jae H Chang
Journal:  ACS Med Chem Lett       Date:  2015-07-12       Impact factor: 4.345

10.  Mechanism-Based Inhibition of CYP3A4 by Podophyllotoxin: Aging of an Intermediate Is Important for in Vitro/in Vivo Correlations.

Authors:  Carlo Barnaba; Jaydeep Yadav; Swati Nagar; Ken Korzekwa; Jeffrey P Jones
Journal:  Mol Pharm       Date:  2016-07-01       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.